Helping our clients move healthcare forward
Deal Announcement
Leerink Partners Deal Announcement: AN2 Therapeutics
Leerink Partners Serves as Joint Bookrunner for AN2 Therapeutics’ (Nasdaq: ANTX) $70 Million Follow-On Offering
Published September 20, 2023More Deal Announcements
View all Deal Announcements
Deal Announcement
Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent to Universal DX on its $70 Million Series B Financing and Strategic Collaboration with Quest Diagnostics
December 2023
Deal Announcement
Leerink Partners Serves as Exclusive Financial Advisor to Freeline Therapeutics (Nasdaq: FRLN) on its Going-Private Transaction with Syncona (LON: SYNC)
November 2023
Deal Announcement
Leerink Partners Serves as Exclusive Financial Advisor and Placement Agent for Q32 Bio’s Proposed Merger with Homology Medicines (Nasdaq: FIXX) and Concurrent $42 Million Private Placement
November 2023
Featured Intelligence
View additional intelligenceSee also:
Capital Markets
Growth-oriented companies need an experienced partner with demonstrated capital-raising power
Learn More